866-997-4948(US-Canada Toll Free)

Bone Cancer Pipeline Review, H2 2012

Published By :

Global Markets Direct

Published Date : Nov 2012

Category :

Cancer

No. of Pages : 212 Pages


Global Markets Directs, \'Bone Cancer Pipeline Review, H2 2012\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Bone Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bone Cancer. 

Bone Cancer Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Bone Cancer.
  • A review of the Bone Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Bone Cancer pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Bone Cancer.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Bone Cancer pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Bone Cancer Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for Bone Cancer 10
Bone Cancer Therapeutics under Development by Companies 12
Bone Cancer Therapeutics under Investigation by Universities/Institutes 15
Late Stage Products 18
Comparative Analysis 18
Mid Clinical Stage Products 19
Comparative Analysis 19
Early Clinical Stage Products 20
Comparative Analysis 20
Discovery and Pre-Clinical Stage Products 21
Comparative Analysis 21
Bone Cancer Therapeutics Products under Development by Companies 22
Bone Cancer Therapeutics Products under Investigation by Universities/Institutes 23
Companies Involved in Bone Cancer Therapeutics Development 28
Genzyme Corporation 28
Amgen Inc. 29
Eli Lilly and Company 30
Merck & Co., Inc. 31
ZIOPHARM Oncology, Inc. 32
Oncolytics Biotech Inc. 33
Simcere Pharmaceutical Group 34
Med Discovery SA 35
Aileron Therapeutics, Inc. 36
Hawthorn Pharmaceuticals, Inc. 37
Virobay Inc. 38
PharmaMar, S.A. 39
Eleison Pharmaceuticals, Inc. 40
Epeius Biotechnologies Corporation 41
Bone Cancer Therapeutics Assessment 42
Assessment by Monotherapy Products 42
Assessment by Combination Products 43
Assessment by Route of Administration 44
Assessment by Molecule Type 46
Drug Profiles 49
cixutumumab - Drug Profile 49
cisplatin - Drug Profile 50
MDRG-01 - Drug Profile 51
ganitumab - Drug Profile 52
cereolysin - Drug Profile 54
VBY-825 - Drug Profile 56
SCH-717454 - Drug Profile 58
PM-00104 - Drug Profile 59
imatinib mesylate - Drug Profile 60
BMTP-11 - Drug Profile 61
Rexin-G - Drug Profile 62
Thiotepa + Stem Cell Transplantation - Drug Profile 64
vincristine sulfate - Drug Profile 65
Bevacizumab + Cisplatin + Doxorubicin + Methotrexate + Ifosfamide + Etoposide - Drug Profile 66
Cyclophosphamide + Sirolimus - Drug Profile 68
proline rich polypeptide - Drug Profile 70
pemetrexed disodium - Drug Profile 71
Reolysin + Cisplatin + Radiation Therapy - Drug Profile 72
Bevacizumab + Vincristine + Topotecan + Cyclophosphamide - Drug Profile 74
Cisplatin + Doxorubicin + Methotrexate + Pamidronate Disodium - Drug Profile 76
Filgrastim + Cisplatin + Doxorubicin - Drug Profile 78
Vincristine + Adiramycin + Actinomycin D + Ifosfamide - Drug Profile 80
G-CSF + Cyclophosphamide + Doxorubicin + Etoposide + Ifosfamide + Vincristine + Radiation Therapy - Drug Profile 81
dasatinib - Drug Profile 83
Cisplatin + Doxorubicin + Etoposide + Ifosfamide + Methotrexate - Drug Profile 84
PEG-interferon Alfa-2b + Cisplatin + Doxorubicin + Methotrexate - Drug Profile 86
Busulfan + Melphalan + Thiotepa + Stem Cell Transplant - Drug Profile 87
Aldesleukin + Tumor Cell B Lymphoblastoid Cell Line Vaccine - Drug Profile 89
Zoledronic Acid + Adriamycin + Cisplatinum + Ifosfamide - Drug Profile 90
zoledronic acid - Drug Profile 92
Vincristine + Doxorubicin + Ifosfamide + Cyclophosfamide + Etoposide + Busulfan + Melfalan + Peripheral Stem Cells Transplantation - Drug Profile 93
treosulfan - Drug Profile 95
Methotrexate + Adrimycin + Cisplatin + Ifosfamide - Drug Profile 96
Methotrexate + Adrimycin + Cisplatin - Drug Profile 97
zoledronic acid - Drug Profile 98
Dactinomycin + Doxorubicin Hydrochloride + Etoposide + Ifosfamide + Vincristine Sulfate + Radiation Therapy - Drug Profile 99
Dactinomycin + Busulfan + Doxorubicin Hydrochloride + Etoposide + Ifosfamide + Melphalan + Vincristine Sulfate + Radiation Therapy + Autologous Peripheral Blood Stem Cell Transplantation - Drug Profile 101
AYRPVSRNI + IFA - Drug Profile 103
AYRPVSRNI + IFA + Interferon Alpha - Drug Profile 104
plerixafor - Drug Profile 105
methotrexate - Drug Profile 107
Temsirolimus + Valproic Acid - Drug Profile 108
Filgrastim + Cisplatin + Dexrazoxane + Doxorubicin + Leucovorin + Methotrexate - Drug Profile 109
Filgrastim + Cisplatin + Dexrazoxane + Doxorubicin + Leucovorin + Methotrexate - Drug Profile 111
XR9576 + Filgrastim + Docetaxel + Doxorubicin Hydrochloride + Vinorelbine Ditartrate - Drug Profile 113
XR9576 + Filgrastim + Docetaxel + Doxorubicin Hydrochloride + Vinorelbine Ditartrate - Drug Profile 115
Filgrastim + Ifosfamide + Peripheral Blood Stem Cell Transplantation + Samarium Sm 153 Lexidronam Pentasodium - Drug Profile 117
Filgrastim + Ifosfamide + Peripheral Blood Stem Cell Transplantation + Samarium Sm 153 Lexidronam Pentasodium - Drug Profile 119
Trimetrexate + Leucovorin - Drug Profile 121
Cyclophosphamide + Doxorubicin + Etoposide + Ifosfamide + Vincristine + Radiation Therapy - Drug Profile 122
Therapeutic Autologous Dendritic Cells + Indinavir Sulfate + Stem Cell Transplantation - Drug Profile 124
Methotrexate + Cisplatin + Doxorubicine - Drug Profile 126
busulfan - Drug Profile 128
Cisplatin + Doxorubicin + Methotrexate - Drug Profile 129
Adriamycin + Cisplatinum + Ifosfamide - Drug Profile 131
Filgrastim SD/01 + Cyclophosphamide + Dexrazoxane + Doxorubicin + Etoposide + Ifosfamide + Vincristine Sulfate + Mesna - Drug Profile 133
Docetaxel + Gemcitabine + Filgrastim + Pegfilgrastim - Drug Profile 136
everolimus - Drug Profile 137
trabectedin - Drug Profile 138
sargramostim - Drug Profile 139
cixutumumab - Drug Profile 140
treosulfan - Drug Profile 142
zoledronic acid - Drug Profile 143
everolimus - Drug Profile 144
haw mAb-11 - Drug Profile 145
Sirolimus + Celecoxib + Etoposide + Cyclophosphamide - Drug Profile 146
RO4929097 + Dexamethasone - Drug Profile 147
palifosfamide + etoposide + carboplatin - Drug Profile 148
Endostar + Methotrexate + Cisplatin + Pirarubicin + Ifosfamide - Drug Profile 150
Dexrazoxane + Doxorubicin + Cisplatin + Methotrexate + Ifosfamide + Etoposide - Drug Profile 152
Cytoxan + Doxorubicin + Vincristine + Irinotecan + Temozolomide + Neulasta + Mesnex - Drug Profile 154
Etoposide + Carboplatin + Cyclophosphamide + Mesna + Melphalan + Tandem Peripheral Blood Stem Cell - Drug Profile 156
Vincristine + Cyclophosphamide + Adriamycin + Etoposide + Cisplatin + Carboplatin + Melphalan + Ifosfamide + Granulocyte-Colony Stimulating Factor + Mesna - Drug Profile 158
Vincristine + Topotecan + Cyclophosphamide + Doxorubicin + Etoposide + Ifosfamide - Drug Profile 160
Vincristine + Doxorubicin + Cyclophosphamide + Dexrazoxane + ImmTher + Mesna + Neupogen + Neulasta - Drug Profile 162
EF-2 Peptide + IL-2 + Autologous T-Cell Transplantation - Drug Profile 164
EF-2 Peptide + IL-2 - Drug Profile 166
PXFK Peptide + IL-2 - Drug Profile 167
PXFK Peptide + IL-2 + Autologous T cell Transplantation - Drug Profile 168
E7 Peptide + IL-2 - Drug Profile 170
E7 Peptide + IL-2 + Autologous T Cell Transplantation - Drug Profile 172
thalidomide - Drug Profile 174
olaparib - Drug Profile 175
aldesleukin Aerosol - Drug Profile 176
plicamycin - Drug Profile 177
Monoclonal Target-6 - Drug Profile 178
p53 Transcription Factor Derived Stapled Peptides - Drug Profile 179
MBC-11 - Drug Profile 180
Bone Cancer Therapeutics Drug Profile Updates 181
Bone Cancer Therapeutics Discontinued Products 188
Bone Cancer Therapeutics - Dormant Products 189
Bone Cancer Product Development Milestones 196
Featured News & Press Releases 196

Appendix 205
Methodology 205
Coverage 205
Secondary Research 205
Primary Research 205
Expert Panel Validation 205
Contact Us 206
Disclaimer 206

List of Table


Number of Products Under Development for Bone Cancer, H2 2012 16
Products under Development for Bone Cancer Comparative Analysis, H2 2012 17
Number of Products under Development by Companies, H2 2012 19
Number of Products under Development by Companies, H2 2012 (Contd..1) 20
Number of Products under Investigation by Universities/Institutes, H2 2012 22
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 23
Comparative Analysis by Late Stage Development, H2 2012 24
Comparative Analysis by Mid Clinical Stage Development, H2 2012 25
Comparative Analysis by Early Clinical Stage Development, H2 2012 26
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 27
Products under Development by Companies, H2 2012 28
Products under Investigation by Universities/Institutes, H2 2012 29
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 30
Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 31
Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 32
Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 33
Genzyme Corporation, H2 2012 34
Amgen Inc., H2 2012 35
Eli Lilly and Company, H2 2012 36
Merck & Co., Inc., H2 2012 37
ZIOPHARM Oncology, Inc., H2 2012 38
Oncolytics Biotech Inc., H2 2012 39
Simcere Pharmaceutical Group, H2 2012 40
Med Discovery SA, H2 2012 41
Aileron Therapeutics, Inc., H2 2012 42
Hawthorn Pharmaceuticals, Inc., H2 2012 43
Virobay Inc., H2 2012 44
PharmaMar, S.A., H2 2012 45
Eleison Pharmaceuticals, Inc., H2 2012 46
Epeius Biotechnologies Corporation, H2 2012 47
Assessment by Monotherapy Products, H2 2012 48
Assessment by Combination Products, H2 2012 49
Assessment by Stage and Route of Administration, H2 2012 51
Assessment by Stage and Molecule Type, H2 2012 54
Bone Cancer Therapeutics Drug Profile Updates 187
Bone Cancer Therapeutics Discontinued Products 194
Bone Cancer Therapeutics Dormant Products 195
Bone Cancer Therapeutics Dormant Products (Contd..1) 196
Bone Cancer Therapeutics Dormant Products (Contd..2) 197
Bone Cancer Therapeutics Dormant Products (Contd..3) 198
Bone Cancer Therapeutics Dormant Products (Contd..4) 199
Bone Cancer Therapeutics Dormant Products (Contd..5) 200
Bone Cancer Therapeutics Dormant Products (Contd..6) 201

List of Chart


Number of Products under Development for Bone Cancer, H2 2012 16
Products under Development for Bone Cancer Comparative Analysis, H2 2012 17
Products under Development by Companies, H2 2012 18
Products under Investigation by Universities/Institutes, H2 2012 21
Late Stage Products, H2 2012 24
Mid Clinical Stage Products, H2 2012 25
Early Clinical Stage Products, H2 2012 26
Discovery and Pre-Clinical Stage Products, H2 2012 27
Assessment by Monotherapy Products, H2 2012 48
Assessment by Combination Products, H2 2012 49
Assessment by Route of Administration, H2 2012 50
Assessment by Stage and Route of Administration, H2 2012 51
Assessment by Molecule Type, H2 2012 52
Assessment by Stage and Molecule Type, H2 2012 53

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *